Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Hodson DJ, Shouse G, Shin HJ, Salar A, Bobillo S, Ribrag V, Macpherson NA, Cordoba R, Kim JS, Guidez S, Herrera AF, Morschhauser F, Colton D, Izuzquiza M, Sambamurthy N, Munugalavadla V, Vicente S, Gorgun G, Chen R, Younes A, Wang ML

Open source

DOI: 10.1158/1078-0432.ccr-25-2239
Published: 2026 Mar 2
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-2239,
  title = {Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).},
  author = {Hodson DJ and Shouse G and Shin HJ and Salar A and Bobillo S and Ribrag V and Macpherson NA and Cordoba R and Kim JS and Guidez S and Herrera AF and Morschhauser F and Colton D and Izuzquiza M and Sambamurthy N and Munugalavadla V and Vicente S and Gorgun G and Chen R and Younes A and Wang ML},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-2239},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-2239}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).
AU  - Hodson DJ
AU  - Shouse G
AU  - Shin HJ
AU  - Salar A
AU  - Bobillo S
AU  - Ribrag V
AU  - Macpherson NA
AU  - Cordoba R
AU  - Kim JS
AU  - Guidez S
AU  - Herrera AF
AU  - Morschhauser F
AU  - Colton D
AU  - Izuzquiza M
AU  - Sambamurthy N
AU  - Munugalavadla V
AU  - Vicente S
AU  - Gorgun G
AU  - Chen R
AU  - Younes A
AU  - Wang ML
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-2239
UR  - https://doi.org/10.1158/1078-0432.ccr-25-2239
ER  -

APA

DJ, H., G, S., HJ, S., A, S., S, B., V, R., NA, M., R, C., JS, K., S, G., AF, H., F, M., D, C., M, I., N, S., V, M., S, V., G, G., R, C., A, Y., & ML, W. (2026). Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-2239

Source records

pubmed · retrieved 2026-09-27T01:36:59.752Z